Zhangjiang company inks collaborative research pact with global institutes

Updated:2019-04-10 (zjsfq.gov.cn)

I-Mab Biopharma from Shanghai's Zhangjiang Science City and Jiangsu Nhwa Pharmaceutical recently announced that they have signed a collaborative research agreement with Brigham and Women's Hospital and Biodextris, a biologics contract development and manufacturing organization.

The cooperation aims to jointly develop a novel immuno-stimulatory therapy system for neurologic disorders by harnessing the natural power of the immune system.

"We are very excited about this collaboration and the potential it brings with it," said Howard L Weiner, co-director of the Ann Romney Center of the Brigham.

The four sides will combine their resources and expertise in basic science, translational research, clinical development, manufacturing, and commercialization, to accelerate the clinical application of innovative immunotherapy methods to aid in the treatment of challenging diseases.

"Brigham is recognized internationally for its excellent innovative practices when it comes to patient care, biomedical research, and education. I-Mab shares the same aspiration and strives to bring innovative treatments to patients around the world,” said Zhang Zheru, president of I-Mab.

The collaboration will accelerate not only drug development but also scientific advancement, Zhang added.

According to the agreement, the Brigham team will be responsible for biomarker discovery and validation, preclinical studies and early clinical trials. Biodextris will be responsible for process development and manufacturing of clinical experimental drugs. I-Mab and Nhwa will provide financial, technical and business support for the preclinical as well as clinical development, and potentially future commercialization. 


I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical sign a collaborative research agreement with Brigham and Women's Hospital and Biodextris at the Ann Romney Center in Boston, Massachusetts, the United States, on April 5, 2019. [Photo/WeChat account: shzjsfq]